Revlimid(Lenalidomide)
BMY
Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Bristol-Myers Squibb Company
$4.18B
Medicare cost, 2024
$4.18B
Medicare cost, 2024
Medicare drug plans spent $4.2 billion on Revlimid (lenalidomide) in 2024, for 239,782 prescriptions and refills filled by 38,856 patients. It ranks 10th among all drugs by Medicare drug plan spending. At about $17,426 per prescription it is a high-cost drug. Florida accounts for the most spending ($404.9 million, 10% of the total).
Medicare cost, 2024
$4.18B
+8.3% from 2023
Prescriptions
240K
$17,426.30 per claim
Patients
39K
11,470 prescribers
Total spending, 2024
$4.18B
$107,530.91 per patient
Questions and answers
How much does Medicare spend on Revlimid?
Medicare prescription drug plans paid $4.18B for Revlimid in 2024, for 239,782 prescriptions and refills to 38,856 patients (up 8.3% from 2023). The average cost per claim was $17,426.30.
Which state spends the most on Revlimid?
Florida had the highest Medicare cost for Revlimid in 2024: $404.9M for 23,726 claims, followed by California ($293.3M).
Who prescribes Revlimid the most?
Parameswaren Venugopal, hematology-oncology in Chicago, IL, had the highest Medicare cost for Revlimid in 2024: 544 claims costing $11.2M.
Who makes Revlimid?
Revlimid is made by Bristol-Myers Squibb Company (BMY), listed in the Medicare spending data as Celgene/BMS.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Revlimid was $4.18B in 2024, after a high of $5.94B in 2022.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Revlimid, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Parameswaren Venugopal Chicago, IL | Hematology-Oncology | 544 | 67 | $11.2M |
| Zachary Hruska Charlottesville, VA | Nurse Practitioner | 587 | 62 | $11.2M |
| John M Burke Aurora, CO | Hematology-Oncology | 418 | 52 | $9.0M |
| Erica L Campagnaro Ann Arbor, MI | Hematology | 428 | 106 | $7.7M |
| Areyl D Goff Milwaukee, WI | Nurse Practitioner | 395 | 88 | $7.7M |
| Catharine E Skoog Milwaukee, WI | Physician Assistant | 413 | 84 | $7.4M |
| Keith E Stockerl-Goldstein Saint Louis, MO | Medical Oncology | 352 | 46 | $7.1M |
| Kerry L Bondy Ann Arbor, MI | Physician Assistant | 384 | 100 | $6.9M |
| Jayesh Mehta Chicago, IL | Hematology | 381 | 60 | $6.9M |
| Sarah A Holstein Omaha, NE | Hematology-Oncology | 398 | 39 | $6.7M |
| Kim A Zawodni Ann Arbor, MI | Nurse Practitioner | 347 | 90 | $6.4M |
| Erica Stevens North Haven, CT | Nurse Practitioner | 350 | 72 | $6.3M |
| Tara B Anderson New Haven, CT | Physician Assistant | 356 | 71 | $6.2M |
| Claudia E Paba Prada Pembroke Pines, FL | Hematology-Oncology | 350 | 40 | $6.1M |
| Ami P Ndiaye Charlotte, NC | Nurse Practitioner | 323 | 107 | $5.9M |
| Patrick A Hagen Maywood, IL | Hematology-Oncology | 317 | 42 | $5.9M |
| Matthew J Pianko Ann Arbor, MI | Hematology | 318 | 82 | $5.8M |
| Suzan Rosen Miami, FL | Nurse Practitioner | 306 | 66 | $5.6M |
| John P Winters III Westbrook, ME | Hematology-Oncology | 307 | 33 | $5.4M |
| Carol Huff Baltimore, MD | Medical Oncology | 299 | 47 | $5.2M |
| Benjamin Derman Chicago, IL | Hematopoietic Cell Transplantation and Cellular Therapy | 280 | 37 | $5.2M |
| Emerentia A Agyemang Boston, MA | Nurse Practitioner | 299 | 61 | $5.2M |
| Yenny Garcia Miami, FL | Nurse Practitioner | 317 | 57 | $5.1M |
| Mark A Schroeder Saint Louis, MO | Hematology-Oncology | 248 | 30 | $4.8M |
| Seth M Maliske Iowa City, IA | Hematopoietic Cell Transplantation and Cellular Therapy | 248 | 34 | $4.7M |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 12,171 | 329,258 | 45,546 | $5.93B |
| 2023 | 11,315 | 216,143 | 36,944 | $3.86B |
| 2024 | 11,470 | 239,782 | 38,856 | $4.18B |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Celgene/BMS | 239,843 | $4.18B |
Medicaid spending by quarter
Amount reimbursed by state Medicaid programs, all states
Amount reimbursed
Codes
- National drug codes (packages)
- 12
- RxNorm concept IDs
- 1242231, 1242233, 1428947, 1429367, 602910
- Application numbers
- NDA021880
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 425,920 side-effect reports named lenalidomide, the active ingredient of Revlimid (reports from 2003 on). 271,850 of them (63.8%) were serious, 54,138 named a death and 110,525 named a hospital stay. The reactions named most often were diarrhoea, fatigue and death. 143,660 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
425,920
23,903 in 2025 (-21.5% from 2024)
Serious
63.8%
271,850 reports
Deaths named
54,138
12.7% of reports
Hospital stays
110,525
25.9% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Revlimid?
425,920 reports from 2003 through September 2026 named lenalidomide, the active ingredient of Revlimid. 271,850 of them (63.8%) were serious, 54,138 named a death and 110,525 named a hospital stay.
What are the most reported side effects of Revlimid?
31,968 reports named diarrhoea, the reaction named most often, followed by fatigue (27,107) and death (26,874). In the last 5 years the reaction named most often was off label use (17,687 reports). A report can name several reactions.
How many side-effect reports named Revlimid in 2025?
23,903 reports were received in 2025 (-21.5% from 2024). 2026 so far: 16,693 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Revlimid caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Revlimid caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Other Medicare drug pages with lenalidomide: Lenalidomide
- Makers on the stock market:
BMY·BMY drug pipeline - Drug approvals (18 approvals on file for lenalidomide) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (lenalidomide) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.